Arrowhead Pharmaceuticals To Advance Investigational Plozasiran Into Phase 3 CAPITAN Cardiovascular Outcomes Trial
– Based on results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease
– CAPITAN builds upon existing SUMMIT program of pivotal Phase 3 clinical studies of plozasiran including PALISADE in patients with familial chylomicronemia syndrome and the SHASTA studies in patients with severe hypertriglyceridemia
– Arrowhead allocating cardiometabolic development and commercial resources to plozasiran and will assess partnership options for future development of zodasiran
– Arrowhead hosting cardiometabolic R&D webinar detailing clinical data and plans to advance plozasiran today, June 25, 2024, at 11:00 am PDT as Part II of the 2024 Summer Series of R&D Webinars